Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler® (Symb NIS)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00532922
First received: September 20, 2007
Last updated: June 8, 2009
Last verified: June 2009
  Purpose

The purpose of this study is to investigate real practices of treatment with Symbicort Turbuhaler for 3 months in asthma and patient compliance.


Condition Phase
Asthma
Phase 4

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler®

Further study details as provided by AstraZeneca:

Enrollment: 310
Study Start Date: April 2007
Study Completion Date: November 2007
Groups/Cohorts
1
Chinese asthma patient prescribed Symbicort® Turbuhaler®

  Eligibility

Ages Eligible for Study:   6 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Natural History, longitudinal, defined population

Criteria

Inclusion Criteria:

  1. Provision of informed consent
  2. Asthmatics who has been prescribed Symbicort according to physician's judgement
  3. Usage of Symbicort should follow local prescribing information

Exclusion Criteria:

  1. Not being involved in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site)
  2. No previous enrolment in the present study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00532922

Locations
China, Anhui
Research Site
Hefel, Anhui, China
China, Fujian
Research Site
Fuzhou, Fujian, China
China, Guangdong
Research Site
Guangzhou, Guangdong, China
Research Site
Shenzhen, Guangdong, China
China, Henan
Research Site
Zhengzhou, Henan, China
China, Hubei
Research Site
Wuhan, Hubei, China
China, Hubel
Research Site
Wuhan, Hubel, China
China, Jiangsu
Research Site
Nanjong, Jiangsu, China
Research Site
Suzhou, Jiangsu, China
China, Liaoning
Research Site
Shenyand, Liaoning, China
China, Shandong
Research Site
Qingdao, Shandong, China
China, Shanxi
Research Site
Taiyuan, Shanxi, China
Research Site
Xi'an, Shanxi, China
China, Sichuan
Research Site
Chengdu, Sichuan, China
China, Zhejiang
Research Site
Wenzhou, Zhejiang, China
China
Research Site
Beijing, China
Research Site
Chongqing, China
Research Site
Hangzhou, China
Research Site
Shanghai, China
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Zhou Xin Shanghai First People's Hospital
Principal Investigator: Hong Jianguo Shanghai First People's Hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00532922     History of Changes
Other Study ID Numbers: NIS-RCN-SYM-2006/1
Study First Received: September 20, 2007
Last Updated: June 8, 2009
Health Authority: Not required for this study:

Additional relevant MeSH terms:
Budesonide
Symbicort
Anti-Asthmatic Agents
Anti-Inflammatory Agents
Autonomic Agents
Bronchodilator Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Respiratory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 25, 2014